Clinical trials: Prostate Cancer Aggressiveness
Prostate Cancer
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer
- Trial name
- NCT03256630
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Genomic Health®, Inc.
Malignant Solid Tumors, Primary Brain Tumor
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour…
- Conditions
- Malignant Solid Tumors, Primary Brain Tumor, Melanoma, Soft Tissue Sarcoma
- Trial name
- REGATA (NCT05539677)
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Prostatic Neoplasms
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate staging of the disease at the time point of diagnosis is important.
- Trial name
- NCT02076503
- Testing
- PET-MR 18f-FACBC, histology (gold standard)
- Where
- Norway
- Volunteers
- 28 people
- Sponsor
- St. Olavs Hospital
Prostatic Neoplasms, Genital Neoplasms, Male
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Prostatic Diseases
- Trial name
- FuncProst (NCT01464216)
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital